Top Story Today
Gilead Bets $7.8B That This CAR-T Therapy Can Break the Myeloma Duopoly
Gilead is acquiring Arcellx for $7.8 billion, scooping up anito-cel, a next-generation CAR-T therapy for multiple myeloma that many analysts expect to become a foundational treatment. The deal is one of the largest cell therapy acquisitions in history, and it's aimed squarely at challenging an increasingly crowded BCMA CAR-T field that includes J&J/Legend's Carvykti, BMS's Abecma, and other recently approved entrants. Gilead already has a foothold in CAR-T through its Yescarta franchise, but myeloma is the bigger prize: a market expected to balloon as more patients become eligible for cell therapy earlier in their treatment journey.
Why it matters: This acquisition validates the thesis that next-gen CAR-T platforms can command mega-deal premiums, and it turns the myeloma market from a duopoly into a three-way fight with serious implications for pricing, patient access, and the competitive calculus of every cell therapy company in the space.
BioPharma Dive →Deals and Dealmaking
$885M for Molecular Glue? The ADC Arms Race Gets Expensive
Earendil signed an $885 million partnership with WuXi XDC to license its linker technology for antibody-drug conjugates (ADCs), the molecular connectors that hold these cancer-targeting missiles together. The deal signals that specialized ADC components, once afterthoughts, are now high-value strategic assets as the oncology field races to build better targeted therapies.
FierceBiotech →AbbVie Drops $650M Upfront on a Bispecific That Targets Oncology's Two Favorite Pathways
AbbVie is paying RemeGen $650 million upfront for rights to a PD-1xVEGF bispecific antibody, combining two of the most validated targets in cancer immunology into one molecule. The deal, announced at JP Morgan, reinforces big pharma's appetite for dual-targeting biologics and keeps the US-China licensing pipeline humming despite geopolitical headwinds.
Endpoints News →Funding and New Ventures
Novartis Bought the Company, but the Leftovers Just Raised $270M
When Novartis paid $12 billion for Avidity Biosciences, not everything fit in the shopping cart. Atrium Therapeutics launched from the remnants with $270 million and two siRNA candidates targeting rare genetic cardiac diseases, with its lead candidate expected to enter the clinic as early as late 2026. It's a masterclass in how mega-acquisitions can spawn entirely new companies.
FierceBiotech →Novo's 'Triple G' Obesity Drug Data Lands in a Crowded Ring
Novo Nordisk released data from its triple-agonist obesity program, a key readout in the increasingly brutal race for next-generation weight loss drugs. The results will shape how Novo positions itself against Lilly's tirzepatide and a growing roster of competitors angling to grab a piece of the obesity market.
STAT News →Policy and Science
The Senate Wants to Know Why Rare Disease Drugs Take So Long
The Senate held a hearing examining the FDA's review process for rare disease treatments, putting orphan drug pathways under a legislative microscope. Any changes to approval timelines, incentive structures, or exclusivity rules could ripple across the hundreds of biotechs whose business models depend on the current orphan drug framework.
FierceBiotech →Psychedelics Without the Trip: Five Discovery's Neuroplastogen Bet
Five Discovery unveiled a platform for non-hallucinogenic neuroplastogens, compounds that promote brain plasticity (the brain's ability to rewire itself) without sending patients on a psychedelic journey. If the science holds, it could sidestep the biggest practical barrier to psychedelic-derived psychiatry treatments: the trip itself.
Business Wire →